RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Artelo Biosciences - Stock

Artelo Biosciences Equity 2024

Artelo Biosciences Equity

11.75 M USD

Ticker

ARTL

ISIN

US04301G2012

WKN

A2PNJU

In 2024, Artelo Biosciences's equity was 11.75 M USD, a -39.42% increase from the 19.4 M USD equity in the previous year.

Artelo Biosciences Aktienanalyse

What does Artelo Biosciences do?

Artelo Biosciences Inc is an innovative biopharmaceutical company specializing in the research and development of new therapies for the treatment of cancer and inflammatory diseases. The company was founded in 2011 and is headquartered in Manchester, UK, with a branch office in San Diego, USA. Artelo Biosciences Inc began with the discovery of new drug candidates based on the body's endocannabinoid system, which plays a crucial role in regulating various physiological processes such as pain, inflammation, mood, and appetite. The company's business model is based on identifying and researching new drug candidates based on the endocannabinoid system, as well as developing and marketing new therapies for the treatment of cancer and inflammatory diseases. Artelo Biosciences Inc operates in various sectors, including cancer therapy, inflammation inhibition, and neurological disorders. In cancer therapy, the company focuses on the development of new drugs for the treatment of solid tumors, particularly triple-negative breast cancer (TNBC), a highly aggressive type of cancer for which there are currently limited therapy options. Artelo Biosciences Inc has several promising drug candidates, including ART27.13, a synthetic cannabinoid receptor agonist that has shown in preclinical studies to inhibit the growth of TNBC cells. In inflammation inhibition, Artelo Biosciences Inc focuses on the development of new drugs for the treatment of diabetes, obesity, and inflammatory bowel diseases. The company has several promising drug candidates, including ART26.12, a synthetic endocannabinoid receptor agonist that has shown in preclinical studies to reduce inflammation in the intestine and improve insulin sensitivity. In neurological therapy, Artelo Biosciences Inc focuses on the development of new drugs for the treatment of anxiety and pain. The company has several promising drug candidates, including ART12.11, a synthetic endocannabinoid receptor agonist that has shown in preclinical studies to reduce anxiety and inhibit pain perception. Artelo Biosciences Inc closely collaborates with leading academic institutions and research centers to develop and test its drug candidates. The company has a strong research and development department composed of highly qualified scientists and clinicians. It also has an effective licensing and marketing strategy to bring its products to market. In summary, Artelo Biosciences Inc is an innovative biopharmaceutical company specializing in the research and development of new therapies for the treatment of cancer and inflammatory diseases. The company's business model is based on identifying and researching new drug candidates based on the endocannabinoid system, as well as developing and marketing new therapies. The company operates in various sectors, including cancer therapy, inflammation inhibition, and neurological disorders. Artelo Biosciences Inc has its own patents and licenses, a strong research and development department, and an effective licensing and marketing strategy to bring its products to market. Artelo Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Artelo Biosciences's Equity

Artelo Biosciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Artelo Biosciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Artelo Biosciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Artelo Biosciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Artelo Biosciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Artelo Biosciences Stock

What is the equity of Artelo Biosciences this year?

Artelo Biosciences has equity of 11.75 M USD this year.

What was the equity of Artelo Biosciences compared to the previous year?

The equity of Artelo Biosciences has increased/decreased by -39.42% decreased compared to the previous year.

What impact does a high equity have on investors of Artelo Biosciences?

A high equity is advantageous for investors of Artelo Biosciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Artelo Biosciences?

A low equity can be a risk for investors of Artelo Biosciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Artelo Biosciences affect the company?

An increase in equity of Artelo Biosciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Artelo Biosciences affect the company?

A reduction in equity of Artelo Biosciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Artelo Biosciences?

Some factors that can affect the equity of Artelo Biosciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Artelo Biosciences so important for investors?

The equity of Artelo Biosciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Artelo Biosciences take to change the equity?

To change equity, Artelo Biosciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Artelo Biosciences pay?

Over the past 12 months, Artelo Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Artelo Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Artelo Biosciences?

The current dividend yield of Artelo Biosciences is .

When does Artelo Biosciences pay dividends?

Artelo Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Artelo Biosciences?

Artelo Biosciences paid dividends every year for the past 0 years.

What is the dividend of Artelo Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Artelo Biosciences located?

Artelo Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Artelo Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Artelo Biosciences from 6/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/17/2024.

When did Artelo Biosciences pay the last dividend?

The last dividend was paid out on 6/17/2024.

What was the dividend of Artelo Biosciences in the year 2023?

In the year 2023, Artelo Biosciences distributed 0 USD as dividends.

In which currency does Artelo Biosciences pay out the dividend?

The dividends of Artelo Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Artelo Biosciences

Our stock analysis for Artelo Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Artelo Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.